Close Menu

Editor's Pick

As an expert in zoonotic viruses, Poon has published an assay for SARS-CoV-2 as well as a characterization of early infection.

The plan piggybacks on national influenza surveillance, testing flu-negative samples using the CDC's rRT-PCR test for the novel coronavirus.

Consumers have filed complaints about the San Diego-based firm's questionable business practices and lack of response in the last year. 

The program aims to consent up to 150,000 patients to a larger biobank program and return selective preemptive PGx results through their medical center physicians.

A recent study established high sensitivity and specificity for three CLIA waived point-of-care molecular flu tests in pediatric samples.

A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.

The bipartisan bill is backed by more than 250 organizations, but ACMG remains opposed, arguing that ordering tests is part of the practice of medicine.

The FDA has been prodding labs performing pharmacogenetic testing, and software firms providing reports from such testing, to undergo regulatory review.

The firm has opened a $10 million Series A financing round that it expects to close in late summer to support running clinical studies for its assay.

Mere weeks after the 2019-nCoV sequence was released, firms, agencies, and research groups have already created PCR-based tests.

Pages